KH 176
CAS No. 2162149-24-6
KH 176 ( KH176 )
产品货号. M13449 CAS No. 2162149-24-6
KH176是Trolox的化学实体衍生物和小分子ROS-氧化还原调节剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥3224 | 有现货 |
|
50MG | ¥16038 | 有现货 |
|
100MG | ¥20250 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称KH 176
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述KH176是Trolox的化学实体衍生物和小分子ROS-氧化还原调节剂。
-
产品描述KH176 is a chemical entity derivative of Trolox and small molecule ROS-redox modulator, shows potential treatment for mitochondrial disorders; retains brain microstructural coherence in the external capsule in Ndufs4 -/- mice and normalizes the increased lipid peroxidation in this area and the cerebral cortex, significantly improves rotarod and gait performance and reduces the degeneration of retinal ganglion cells in Ndufs4 -/- mice.Other Indication Phase 2 Clinical.
-
体外实验——
-
体内实验Sonlicromanol (KH176) hydrochloride maintains microstructural coherence in the brain of Ndufs4?/? mice. Animal Model:Ndufs4?/? mice (Leigh Disease model).Dosage:10?mg/kg.Administration:IP, daily (PD14-PD45, 32 days).Result:Significantly improve rotarod and gait performance and reduced the degeneration of retinal ganglion cells.Resulted in statistically significantly higher FA values in the external capsule and a similar trend was found in the cerebral peduncle.
-
同义词KH176
-
通路Others
-
靶点Other Targets
-
受体Other Targets
-
研究领域Other Indications
-
适应症Other Disease
化学信息
-
CAS Number2162149-24-6
-
分子量368.902
-
分子式C19H29ClN2O3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 170 mg/mL (460.83 mM)
-
SMILES——
-
化学全称(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. de Haas R, et al. Sci Rep. 2017 Sep 15;7(1):11733.
2. Koene S, et al. Orphanet J Rare Dis. 2017 Oct 16;12(1):163.
产品手册
关联产品
-
Azomycin
阿佐霉素是一种由肠系膜诺卡氏菌菌株产生的抗菌抗生素。
-
Pseudobufarenogin
Pseudobufarenogin 是一种新型抗肿瘤化合物,通过抑制受体酪氨酸激酶介导的信号传导来抑制肝癌生长。
-
Decuroside I
Decuroside I shows weak inhibiting activity against the primary and secondary wave aggregation of human platelet.